Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.51 |
| ▸ | CDK2 | P24941 | 7/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCND1 | P24385 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10103846 | 0.81 | RAB9A (0.59) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL2513287 | 0.79 | ALDH1A1 (0.37) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL14837553 | 0.79 | LMNA (0.37) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL2512774 | 0.79 | ALDH1A1 (0.37) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL473490 | 0.78 | RAB9A (0.59) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL14837525 | 0.77 | GRM2 (0.41) | RAB9AMAPK8MAPK9CDK2MAPK10 | |
| SCHEMBL7024738 | 0.75 | ROCK1 (0.62) | RPS6KA5POLB | |
| SCHEMBL3824181 | 0.75 | MKNK1 (0.48) | MAPK8MAPK9CDK2MAPK10SMN1; SMN2 | |
| SCHEMBL10104143 | 0.75 | RAB9A (0.52) | RAB9AMAPK8MAPK9CCNE1CDK2 | |
| SCHEMBL473574 | 0.75 | MAPK8 (0.56) | RAB9AMAPK8MAPK9CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962622-B2 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC (US) | 2015-02-24 | — | — | US | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| EP-2066319-B1 | BENZOTRIAZOLE KINASE MODULATORS | HOFFMANN LA ROCHE (CH) | 2012-02-01 | — | — | EP | disclosed |
| CN-101511359-A | Benzotriazole kinase modulators | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | CN | disclosed |
| EP-2066319-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| US-20080103142-A1 | Benzotriazole kinase modulators | ROCHE PALO ALTO LLC | 2008-05-01 | — | — | US | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028860-A1 | BENZOTRIAZOLE KINASE MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103142-A1 | Benzotriazole kinase modulators | CDK1, CDK3, MAPK1 | RAB9A 3749/4885MAPK8 61/4885MAPK9 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.